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Attenuation of tubular apoptosis by blockade of the renin- have been the subject of investigation, the pathogenesis
angiotensin system in diabetic Ren-2 rats. of tubular atrophy remains poorly understood. Recently,
Background. Tubular atrophy is a major feature of most re- several studies have suggested that apoptosis rather thannal diseases and is closely associated with loss of renal function.
necrosis may account for tubular atrophy in human asThe present study sought to investigate tubular epithelial cell
apoptosis in experimental diabetic nephropathy and to explore well as experimental chronic renal disease [3, 4].
the role of pro-apoptotic [transforming growth factor- (TGF-) Certain renal growth factors have been pathogenet-
and anti-apoptotic growth factors [epidermal growth factor ically linked to disease progression and apoptosis while(EGF)]. The effects of renoprotective therapy with blockade
others may protect cells from injury. For instance, trans-of the renin-angiotensin system (RAS) also were examined.
Methods. Six-week-old female Ren-2 rats were injected with forming growth factor- (TGF-) has been consistently
streptozotocin (STZ) and maintained diabetic for 12 weeks. implicated in the induction of both glomerulosclerosis
Further groups of diabetic rats were treated with the angioten- and tubulointerstitial fibrosis in a wide range of renalsin-converting enzyme (ACE) inhibitor, perindopril, or the
diseases including diabetic nephropathy [5, 6]. In addi-angiotensin II type 1 (AT1) receptor antagonist, valsartan, for
tion, to its pro-fibrotic effects TGF- also may contribute12 weeks.
Results. Widespread apoptosis, identified immunohistochem- to renal disease progression by its potent pro-apoptotic
ically by single stranded DNA and TUNEL, was noted in the activity [7]. In contrast, epidermal growth factor (EGF)
tubules of diabetic Ren-2 rats. These changes were associated
is a renotrophic growth factor that is implicated morewith a 50% decrease in EGF expression and a twofold increase
in the recovery from renal injury and the protection fromin TGF-1 mRNA. Treatment of diabetic Ren-2 rats with either
valsartan (20 mg/kg/day) or perindopril (6 mg/kg/day) reduced apoptotic cell death [8, 9].
apoptosis to control levels in association with supranormal Blockade of the renin-angiotensin system (RAS) is a
levels of EGF mRNA (P  0.01) and a reduction in TGF-1
major therapeutic strategy in both diabetic [10] and non-gene expression (P  0.05) to that of control rats.
diabetic renal disease [11], with evidence of effects be-Conclusions. Tubular apoptosis is a prominent feature of
diabetic Ren-2 rats that is attenuated by blockade of the RAS in yond amelioration of systemic and intraglomerular hy-
association with modulation of pro- and anti-apoptotic growth pertension [12]. Indeed, in addition to their beneficial
factor expression.
effects on renal function, angiotensin-converting enzyme
(ACE) inhibitors and angiotensin-II type 1 (AT1) recep-
tor antagonists also have been shown to reduce tubularTubulointerstitial injury, characterized by interstitial
injury in inflammatory, metabolic [13], hemodynamicfibrosis and tubular atrophy, is a major feature of most
[14] and mechanically induced renal injury [15].renal diseases including diabetic nephropathy [1]. Both
The transgenic (mRen-2)27 rat with the mouse Ren-2interstitial fibrosis and tubular atrophy are closely associ-
gene inserted into the genome of a Sprague-Dawley ratated with loss of renal function [2]. While the mecha-
overexpresses renin and angiotensin II (Ang II) at sitesnisms underlying the development of interstitial fibrosis
of normal physiological expression [16]. When rendered
diabetic, the Ren-2 rat develops advanced glomerulo-Key words: cell death, transgenic rats, diabetic nephropathy, tubulo-
interstitial disease, growth factors, renoprotection. sclerosis and tubulointerstitial disease with concomitant
renal impairment [5, 17]. Indeed, as in diabetic kidney
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tool to examine the cellular mechanisms responsible for 200 mL of fixative) to fix the tissues [17]. Kidneys were
removed from the animal, decapsulated and sliced trans-the progression of diabetic nephropathy.
In the present study, we sought to investigate tubular versely. Kidneys were post-fixed in the same fixative for
two hours, routinely processed, embedded in paraffin andepithelial cell apoptosis in relation to expression of both
pro- and anti-apoptotic growth factors in experimental sectioned.
diabetic nephropathy and to examine the effects of RAS
Histopathologyblockade on these parameters.
Tubular pathology was assessed on kidney sections
stained with a modified Masson’s trichrome stain [17].
METHODS
Tubular atrophy and fibrosis were quantified in tri-
Animals chrome stained kidney section as previously described
[5, 14]. In brief, under high power magnification (200)Six-week-old female, heterozygous Ren-2 rats, weigh-
ing 125 5 g were randomized to receive either 55 mg/kg five random and non-overlapping fields from each slide
(N  6/group) were captured and digitized using a Fujixof streptozotocin (STZ; Sigma, St. Louis, MO, USA)
diluted in 0.1 mol/L citrate buffer, pH 4.5 (diabetic) or HC-2000 digital camera (Fuji, Tokyo, Japan). The rela-
tive percentage of atrophic tubules and fibrosis (bluecitrate buffer alone (non-diabetic) by tail vein injection
following an overnight fast [17]. Female rats were studied stain) was quantitatively measured [18], using computer-
ized image analysis (AIS, Ontario, Canada).because they do not require maintenance antihyperten-
sive therapy and hence have a lower systolic blood pres-
Immunohistochemistrysure. Diabetic and non-diabetic Ren-2 rats (N  6 per
group) were treated either with an ACE inhibitor, perin- Three-micron sections were placed into histosol to re-
move the paraffin wax, hydrated in graded ethanol, anddopril (Servier Laboratories, Paris, France; average dose,
6 mg/kg/day), or an AT1 receptor antagonist, valsartan immersed into tap water before being incubated for 20
minutes with normal goat serum (NGS) diluted 1:10 with(20 mg/kg/day), for 12 weeks post-STZ, or vehicle. All rats
were housed in a stable environment (maintained at 22 0.1 mol/L PBS at pH 7.4. Sections were then incubated
for 18 hours at 4C with specific monoclonal antisera to1C with a 12-hour light/day cycle) and allowed free ac-
cess to tap water and standard rat chow containing 0.25% single-stranded DNA (ssDNA; Alexis Biochemicals, San
Diego, CA, USA) to evaluate apoptosis. Sections incu-Na and 0.76% K (GR2; Clark-King & Co., Gladesville,
NSW, Australia). Each week, rats were weighed and bated with 1:10 NGS instead of the primary antiserum
served as the negative control. After thorough washingblood glucose (non-diabetic, 4 to 8 mmol/L; diabetic,
18 to 25 mmol/L) was determined using an AMES glu- with PBS (3  5 min changes), the sections were flooded
with a solution of 5% hydrogen peroxide, rinsed withcometer (Bayer Diagnostics, Melbourne, Australia). Di-
abetic rats received a daily injection of insulin (2 to 4 PBS (2  5 min), and incubated with biotinylated goat
anti-rabbit IgG (Dakopatts, Glostrup, Denmark) dilutedunits IP; Ultratard, Novo Nordisk, Denmark) to main-
tain an average daily blood glucose of between 18 and 1:200 with PBS. Sections were rinsed with PBS (2 
5 min) and incubated with an avidin-biotin peroxidase25 mmol/L, to promote weight gain, reduce ketoacidosis
and reduce mortality [17]. Experimental procedures ad- complex (Vector, Burlingame, CA, USA) diluted 1:200
with PBS. Following rinsing with PBS (2  5 min), sec-hered to the guidelines of the National Health and Medi-
cal Research Council of Australia’s Code for the Care tions were incubated with 0.05% diaminobenzidine and
0.05% hydrogen peroxide (Pierce, Rockford, IL, USA)and Use of Animals for Scientific Purposes and were
approved by the Bioethics Committee of the University in PBS at pH 7.6 for one to three minutes, rinsed in tap
water for five minutes, counterstained in Mayer’s hema-of Melbourne.
toxylin, differentiated in Scott’s tap water, dehydrated,
Tissue preparation cleared and mounted in Depex.
Rats were anesthetized (Nembutal, 60 mg/kg body wt
TUNELIP; Boehringer-Ingelheim, Parramatta, NSW, Australia)
and the abdominal aorta cannulated with an 18 G needle. Cell death was identified by 3 in situ end labeling of
fragmented DNA with biotinylated deoxyuridine-tri-Perfusion-exsanguination commenced at 180 to 220 mm Hg
via the abdominal aorta with 0.1 mol/L phosphate buf- phosphate (dUTP) as previously described [19].
In brief, sections of formalin fixed tissue were dewaxedfered saline (PBS), pH 7.4 (20 to 50 mL) to remove circu-
lating blood and the inferior vena cava adjacent to the and hydrated. Following digestion with Proteinase K
(2 	g/mL; Sigma), sections were consecutively washedrenal vein was simultaneously severed allowing free flow
of the perfusate. After clearance of circulating blood, in TdT buffer (0.5 mol/L cacodylate pH 6.8, 1 mmol/L
cobalt chloride, 0.15 mol/L NaCl) and then incubated at4% paraformaldehyde in 0.1 mol/L phosphate buffer,
pH 7.4 was perfused for a further five minutes (100 to 37C with TdT (25 U, Boehringer-Mannheim, Mann-
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heim, Germany) and biotinylated dUTP (1 nmol/	L). erol in distilled water; Ilford, Moberly, Cheshire, UK),
After washing in TB buffer (300 mmol/L NaCl, 30 mmol/L stored with desiccant at room temperature for 21 days,
sodium citrate) to terminate the reaction, incorporation developed in Ilford phenisol, fixed in Ilford Hypam and
of biotinylated dUTP was detected by a modification of stained with hematoxylin and eosin (H&E).
the ABC method as previously reported. A mouse spleen
with increased apoptosis was used as a positive control Quantitation of immunohistochemistry and
for TUNEL. The omission of TdT during dUTP nick in situ hybridization
end labeling provided a negative control [19]. The levels of gene expression of EGF and TGF-were
assessed by two different methods. The first approachIn situ hybridization
considered the kidney as separate cortical and medullaryA 985 bp cDNA coding for rat TGF-1 (gift of Dr.
components and involved densitometric evaluation ofQian, Bethesda, MD, USA) was cloned into pBluescript
autoradiographic images. The second approach exploredKS (Stragene Inc., La Jolla, CA, USA). The cDNA was
the possibility that there were cell specific changes inthen linearized with XbaI and an antisense probe was
response to diabetes by quantitating the area of auto-generated using T3 RNA polymerase. The 400 bp cDNA
radiographic grains within specific components of the kid-probe for EGF was cloned into pGEM 3Z (Promega,
ney [18]. Tissue sections from all animals were exposedMadison, WI, USA) and linearized with HindIII to pro-
to x-ray film for five days and exposed to photographicduce an antisense riboprobe (NEN, Boston, MA, USA)
using T7 RNA polymerase. Antisense riboprobes were emulsion for 14 days. All analyses were performed with
then labeled with [33P]UTP and in situ hybridization was the observer masked to the animal study group.
performed as previously described. In brief, tissue sec- Densitometry of autoradiographic images obtained by
tions were dewaxed, rehydrated, and then digested with in situ hybridization was performed by computer-assisted
Pronase E [125 	g/mL in 50 mmol/L Tris-HCl, pH 7.2, image analysis as previously described [18] according
5 mmol/L ethylenediaminetetraacetic acid (EDTA), pH to the methods of Baskin and Stahl [20] using an AIS
8.0] at 37C for 10 minutes. After 2  2 minutes rinses (Analytical Imaging System, St. Catherine’s, Ontario,
in 0.1 mol/L phosphate buffer, pH 7.2, sections were Canada). In brief, in situ autoradiographic images were
fixed in 4% paraformaldehyde, pH 7.4 for 10 minutes at placed on a uniformly-illuminating fluorescent light box
room temperature and rinsed again in 0.1 mol/L phos-
(Northern Light Precision Luminator Model C60, Imagephate buffer. Sections were then dehydrated through
Research, Ontario, Canada) and captured using a digitalgraded ethanol and air-dried. Sections were hybridized
camera (Fujix HC 2000, Tokyo, Japan) connected to anwith 33P-labeled anti-sense EGF and TGF-1 probes (5
IBM Pentium III computer with a 1024  1240 pixel105 cpm/25 	L hybridization buffer) in hybridization
array imaging board. Following appropriate calibrationbuffer (300 mmol/L NaCl, 10 mmol/L Tris-HCl, pH 7.5,
by constructing a curve of optical density versus radio-10 mmol/L Na2HPO4, pH 6.8, 5 mmol/L EDTA, pH 8.0,
activity [21] quantitation of digitized autoradiographic1  Denhardt’s solution, 0.8 mg yeast RNA/mL, 50%
images was performed using imaging software (AIS).deionized formamide and 10% dextran sulfate), heated
to 85C and 25	L added to the sections. Sections hybrid- Fifteen non-overlapping 150-	m fields from the kidney
ized with sense probe for EGF and TGF-1 were used as of each rat were quantified as an index of gene expres-
controls for non-specific binding. Coverslips were placed sion. Data were expressed as optical density (OD).
on the sections and the slides incubated in a humidified In the second approach, changes in expression of EGF
chamber (50% formamide/2  SSC) at 60C for 14 to and TGF-within the kidney were explored. Using tissue
16 hours. Slides were then washed in 2 SSC (0.3 mol/L sections exposed to photographic emulsion for three
NaCl, 0.33 mol/L Na3C6H5O7·2H2O) containing 50% for- weeks were examined. Dark-field images were captured
mamide at 50C to remove the coverslips. The slides were and digitized using a Fujix HC-2000 digital camera (Fuji).
again washed with 2 SSC, 50% formamide for a further Regional gene expression was quantitatively measured
one hour at 55C. Sections were then rinsed three times
to determine the proportion of each area occupied byin RNase buffer (10 mmol/L Tris-HCl, pH 7.5, 1 mmol/L
autoradiographic grains as previously described [18], us-EDTA, pH 8.0, 0.5 mol/L NaCl) at 37C and treated
ing computerized image analysis (AIS). All sections werewith 150 	g RNase A/mL in RNase buffer for a further
hybridized to their respective probes in the same experi-one hour at 37C, then washed with 2  SSC at 55C for
ment and were analyzed in duplicate [18].45 minutes. Finally, sections were dehydrated through
For quantitation of immunohistochemistry, the num-graded ethanol, air dried and exposed to Kodak Biomax
ber of positive tubular cells for either TUNEL or ssDNAMR Autoradiography film (Eastman Kodak, Rochester,
was counted in three to five randomly chosen sectionsNY, USA) for four days at room temperature. Slides
were coated with Ilford K5 emulsion (1:1 with 2% glyc- from each group (N  6 per group).
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Table 2. Quantitation of epidermal growth factor (EGF) andTable 1. Body weight, kidney weight, systolic blood pressure and
plasma glucose in control, diabetic and diabetic rats transforming growth factor- (TGF-) mRNA in autoradiographs
of kidney cortex and medulla from control, diabetic andtreated with perindopril or valsartan
diabetic rats treated with perindopril or valsartan
Body Kidney
Blood Plasmaweight weight TGF-
EGFKW/BW pressure glucose
g 10
3 mm Hg mmol/L cortex Medulla Cortex Medulla
Control 0.250.03 0.290.04 0.090.03 0.040.03Control 2928 1.910.17 6.50.2 2099 5.40.2
Diabetic 2217a 2.010.26 9.10.3a 21411 20.61.0b Diabetic 0.150.03a 0.310.04 0.250.04b 0.110.04a
Perindopril 0.420.03ad 0.580.05bd 0.110.02d 0.040.02cPerindopril 2687ac 1.890.47 7.10.6 1405ac 19.51.0b
Valsartan 24312ac 1.960.24 8.10.6 1354ac 21.20.7b Valsartan 0.390.03ad 0.540.04bd 0.100.06d 0.040.02c
Data are expressed as mean  SEM; N  6 per group. KW/BW, kidney Data are expressed as mean SEM. EGF and TGF- are expressed as relative
optical density (N  6 per group).weight/body weight ratio.
a P  0.05, b P  0.01 when compared to control a P  0.05, b P  0.01 when compared to control
c P  0.05, d P  0.01 when compared to diabeticc P  0.05 when compared to diabetic
Fig. 1. Low-resolution autoradiographs of transforming growth fac-
tor- (TGF-) mRNA in the kidney of Ren-2 rats. (A) Control, (B)
diabetic, (C ) diabetic treated with perindopril, (D) diabetic treated
with valsartan. With diabetes TGF- is increased when compared to
Fig. 2. Low-resolution autoradiographs of growth factor mRNA in thecontrols while treatment was associated with decreased TGF- mRNA
kidney of Ren-2 rats. (A) Control, (B) diabetic, (C ) diabetic treatedlevels, similar to that of controls. Magnification 5.
with perindopril, (D) diabetic treated with valsartan. With diabetes
there is reduced EGF mRNA when compared to controls while treat-
ment was associated with increased EGF mRNA to levels above that
of controls (magnification 5).
Statistics
Data are expressed as means  SEM unless other-
wise stated. Statistical significance was determined by
RESULTSANOVA with a Fisher post-hoc comparison. Analyses
were performed using Statview II  Graphics package Rats that received STZ were all diabetic (Table 1).
Diabetes was associated with reduced body mass but(Abacus Concepts, Berkeley, CA, USA) on an Apple
Macintosh G3 computer (Apple Computer, Inc., Cuper- without change in kidney weight when compared with
control animals. Thus, when compared to control ani-tino, CA, USA). A P value0.05 was regarded as statis-
tically significant. mals, the kidney weight/body weight ratio was increased
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Fig. 3. In situ hybridization of renal EGF
mRNA in the Ren-2 rat. Sections stained with
H&E. In control (A) kidneys, EGF mRNA
was localized to distal tubules and diabetes (B)
was associated with decreased distal tubular
EGF gene expression. Both perindopril (C )
and valsartan (D) treatment were associated
with increased EGF mRNA in distal tubules
of diabetic rats (magnification 340).
Table 3. Quantitation of EGF and TGF- in situ hybridization in In situ hybridization microscopy
the kidney of control, diabetic and diabetic rats treated with
perindopril or valsartan In control animals, EGF mRNA was localized to the
distal convoluted tubules and collecting ducts of the kid-EGF TGF-
ney. No EGF mRNA was detected in the glomerulus.%
Compared with control animals, EGF mRNA in diabetic
Control 6.11 0.120.02
rat distal tubules (Fig. 3B) was decreased and there wasDiabetic 3.41.8a 1.240.21a
Perindopril 27.23.5bc 0.510.04ac no change in EGF mRNA in the collecting ducts. Treat-
Valsartan 33.22.7bc 0.420.06ac ment with perindopril or valsartan increased the expres-
Data are expressed as mean  SEM. EGF and TGF- are expressed as % sion of EGF mRNA in both the distal tubules and thearea of grains per tubular area (N  6 per group).
a P  0.05, b P  0.01 when compared to control collecting ducts to greater than that found in control
c P  0.05 when compared to diabetic
animals (Table 3, Fig. 3). Sections labeled with sense
probe showed no hybridization.
Immunohistochemistryin diabetic rats (Table 1). Control and diabetic rats were
hypertensive, and treatment with both perindopril and In control animals, EGF immunolabeling was present
valsartan reduced the blood pressure to normotensive in the distal convoluted tubules and collecting ducts of
levels (Table 1). the kidney. No EGF immunolabeling was detected in
the glomerulus. Compared with control animals, kidneyLow resolution autoradiography
EGF immunolabeling in diabetic rat distal tubules ap-
Compared with control animals, TGF- mRNA in peared to decrease. Treatment with perindopril or val-
diabetic rat kidneys was increased, while perindopril and sartan was associated with an increase in distal tubular
valsartan both attenuated the level of TGF- gene ex-
and collecting duct EGF immunolabeling to above thatpression to that similar to controls (Table 2, Fig. 1).
of controls (Fig. 4).In control animals, EGF mRNA was noted in the
cortex and the outer medulla. Compared with control
Apoptosisanimals, EGF mRNA was decreased in the cortex of
Tubular apoptosis, as indicated by the immunolabelingdiabetic rat kidneys, while perindopril or valsartan treat-
for ssDNA monoclonal antibody and TUNEL was in-ment increased the level of EGF mRNA in both the
creased with diabetes and reduced with either perindo-cortex and outer medulla to above that of controls (Ta-
ble 2, Fig. 2). pril or valsartan treatment (Table 4, Fig. 5).
Kelly et al: Tubular apoptosis in diabetic nephropathy36
Fig. 4. Immunolabeling for EGF in the kid-
ney of Ren-2 rats. Sections counterstained
with Mayer’s hematoxylin. In control (A) kid-
neys, EGF immunolabeling was localized to
distal tubules and diabetes (B) was associated
with decreased distal tubular EGF immuno-
labeling. Both perindopril (C ) and valsartan
(D) treatment were associated with increased
EGF immunolabeling in distal tubules from
diabetic rats (magnification 340).
Table 4. Quantitation of apoptosis and tubular atrophy and Indeed, in the present study, not only was renal injury
fibrosis in control, diabetic and diabetic rats treated with
in the diabetic Ren-2 rat associated with significant tubu-perindopril or valsartan
lointerstitial fibrosis and tubular epithelial cell apoptosis,
Tubular Tubular but renoprotective therapy with RAS blockade amelio-TUNEL ssDNA fibrosis atrophy
rated this mode of cell loss. Furthermore, tubular cells
Control 2.41.2 1.20.8 5.11.1 0.50.2
from untreated diabetic Ren-2 rats expressed an injury-Diabetic 65.311.2b 48.49.7b 19.23.5b 10.21.1b
Perindopril 25.68.5ac 16.73.6ac 3.80.7ac 2.11.0ac associated growth factor phenotype, with a reduction in
Valsartan 19.37.3ac 18.23.1ac 3.40.9ac 2.00.9ac EGF expression and a concomitant increase in TGF-
Data expressed as mean SEM. TUNEL and ssDNA are expressed as positive mRNA [5]. These phenotypic changes were reversed by
nuclei per field (N  6 per group). Tubule atrophy and fibrosis are expressed
blockade of the RAS with both ACE inhibition and AT1as percentage area per 5 tissue sections.
a P  0.05, b P  0.01 when compared to control receptor blockade
c P  0.05 when compared to diabetics
The mammalian kidney, particularly the distal tubule,
is a major site of constitutive EGF synthesis, where it is
thought to act in a paracrine or autocrine manner [23, 24]
Tubulointerstitial fibrosis and atrophy to modulate a variety of cell functions including cellular
metabolism and growth [25]. In the present study, experi-Diabetic rats were associated with significant tubular
mental diabetic nephropathy was associated with a re-atrophy and fibrosis when compared to controls (Table
duction in EGF expression suggesting an alteration in4, Fig. 6). Treatment with either perindopril or valsartan
the normal tubular phenotype in response to renal injury.was associated with a significant reduction in both tubu-
These findings are consistent with the reduction in renallar fibrosis and atrophy.
EGF reported in both incipient and overt diabetic ne-
phropathy [26] and in tubulointerstitial nephritis in hu-
DISCUSSION mans [27]. Similarly, reduced renal EGF expression has
The extent of tubulointerstitial injury correlates closely also been noted in several models of experimental renal
with long-term renal function in a variety of primary disease including chronic allograft rejection [28], renal
glomerular diseases. In particular, tubular atrophy has ischaemia [29] and ureteric obstruction [30]. These mod-
long been recognized as an indicator of renal disease els contrast the findings in renal hypertrophy where renal
severity and progression [2, 22]. While such tubular atro- architecture is preserved and EGF expression is tran-
phy with its attendant tubular epithelial cell loss may siently increased [31], suggesting that injury rather than
be the result of necrosis, the absence of the attendant growth leads to a reduction in EGF expression. Indeed,
cytological features in most chronic renal disease sug- activation of the EGF receptor may have a renoprotec-
gests that apoptosis may be the predominant mechanism tive phenotype. For instance, the administration of exog-
enous EGF accelerates the recovery from nephrotoxicunderlying epithelial cell deletion in the injured kidney.
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Fig. 5. Immunolabeling for TUNEL in the kid-
ney of Ren-2 rats. Sections counterstained with
eosin. In control rats (A), TUNEL immuno-
labeling was barely detected while diabetic rats
had increased immunolabeling for TUNEL (B).
Both perindopril (C ) and valsartan (D) treat-
ment were associated with decreased TUNEL
positive tubules (magnification 340).
Fig. 6. Masson’s trichrome stained section of
kidney cortex representing the proportion of
tubular atrophy and fibrosis in Ren-2 rats. In
control rats (A), there is very little collagen
deposition within the interstitium and no tu-
bular atrophy. However, in the diabetic rats
(B) there is significant tubular atrophy (*) and
increased tubulointerstitial fibrosis (arrow).
Both perindopril (C ) and valsartan (D) treat-
ment were associated with decreased tubular
atrophy and fibrosis (magnification 340).
injury [32, 33], ischemia [34], and mechanical obstruction elucidated, recent evidence suggests that activation of
the EGF receptor by exogenous EGF [35] or endogenous[35]. Furthermore, a related renal growth factor, heparin-
binding EGF-like growth factor (HB-EGF), which also HB-EGF [36] inhibits tubular epithelial cell apoptosis.
In the present study, blockade of the RAS with bothsignals via the EGF receptor, appears to endogenously
exert a renoprotective effect in experimental animals with ACE inhibition and AT1 receptor antagonism was asso-
ciated with up-regulation in EGF expression to su-obstructive uropathy [36]. While the mechanisms medi-
ating this renoprotective effect of EGF have not been pranormal levels in association with reduced apoptosis
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mens from patients with persistent glomerular nephritis. Lancetand tubular atrophy. These findings suggest that the re-
2:363–366, 1968
noprotective effects of RAS blockade may be mediated, 3. Schelling JR, Nkemere N, Kopp JB, Cleveland RP: Fas-depen-
dent fratricidal apoptosis is a mechanism of tubular epithelial cellat least in part, by an increase in endogenous EGF.
deletion in chronic renal failure. Lab Invest 78:813–824, 1998Transforming growth factor- is a pleiotropic growth
4. Schelling JR, Cleveland RP: Involvement of Fas-dependent
factor with effects on cell proliferation and differentia- apoptosis in renal tubular epithelial cell deletion in chronic renal
failure. Kidney Int 56:1313–1316, 1999tion as well as its actions on extracellular matrix synthesis
5. Kelly DJ, Skinner SL, Gilbert RE, et al: Effects of endothelinand degradation [37]. In addition to cell cycle arrest,
or angiotensin II receptor blockade on diabetes in the transgenic
TGF- induces apoptosis in a wide range of cells includ- (mRen-2)27 rat. Kidney Int 57:1882–1894, 2000
6. Ziyadeh FN: Role of transforming growth factor beta in diabeticing glomerular capillary endothelial cells [38], uterine
nephropathy. Exp Nephrol 2:137, 1994epithelial cells [39] and hepatocytes [40]. However, the
7. Huang Y, Hutter D, Liu Y, et al: Transforming growth factor-
pro-apoptotic activity of TGF- may be altered by the beta 1 suppresses serum deprivation-induced death of A549 cells
through differential effects on c-Jun and JNK activities. J Biolpresence of other growth factors. In particular, EGF has
Chem 275:18234–18242, 2000been shown to reduce TGF- induced apoptosis in vitro
8. Gibson S, Tu S, Oyer R, et al: Epidermal growth factor protects
[9, 41] and in oligonephronal models of chronic renal epithelial cells against Fas-induced apoptosis. Requirement for
Akt activation. J Biol Chem 274:17612–17618, 1999disease in vivo [3].
9. Isfort RJ, Cody DB, Stuard SB, et al: The combination of epider-The interaction between EGF and the RAS is com-
mal growth factor and transforming growth factor-beta induces
plex. For instance, EGF is a potent inhibitor of renin se- novel phenotypic changes in mouse liver stem cell lines. J Cell Sci
110:3117–3129, 1997cretion [42]. In human diabetic nephropathy [43], as in
10. Lewis ES, Hunsicker LG, Bain RP, Rohde RD: The effect ofthe diabetic Ren-2 rat [17] and subtotally nephrecto-
angiotensin converting enzyme inhibition on diabetic nephropathy.
mized rat [44], renin expression by the tubular epithelium New Engl J Med 329:1456–1462, 1993
11. Ruggenenti P, Perna A, Mosconi L, et al: Proteinuria predictsis dramatically increased. These changes are accompa-
end-stage renal failure in non-diabetic chronic nephropathies. Thenied by increased angiotensin II formation by tubular
“Gruppo Italiano di Studi Epidemiologici in Nefrologia” (GISEN).
epithelial cells and overexpression of TGF- [44, 45]. It Kidney Int 52(Suppl 63):S54–S57, 1997
12. Border WA, Noble NA: Interactions of transforming growth fac-is therefore possible that some of the beneficial effects of
tor-beta and angiotensin II in renal fibrosis. Hypertension 31:181–ACE inhibition and AT1 receptor antagonist, as indicated
188, 1998
in the present study, may result from an EGF-mediated 13. Gilbert RE, Cox A, Wu LL, et al: Expression of transforming
growth factor-beta and type IV collagen in the renal tubulointerstit-reduction in tubular renin expression, with consequent
ium in experimental diabetes: Effects of angiotensin convertingdiminution in Ang II-dependent TGF- synthesis.
enzyme inhibition. Diabetes 47:414–422, 1998
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